- A Pilot Study of Bortezomib in Korean Patients with Relapsed or Refractory Myeloma
-
Lee KW, Yun T, Song EK, Na II, Shin H, Bang SM, Lee JH, Lee ST, Kim JH, Yoon SS, Lee JS, Park S, Kim BK, Kim NK
- KMID: 1712739
- J Korean Med Sci.
- 2005 Aug;20(4):598-602.
- doi: 10.3346/jkms.2005.20.4.598
Recent clinical trials showed that bortezomib, a novel proteasome inhibitor, had therapeutic activity in multiple myeloma. However, there was no data about the feasibility of bortezomib in Korean patients. We... -
- CITED
-
- Close
- SHARE
-
- Close
- The Effect of Bortezomib on Expression of Inflammatory Cytokines and Survival in a Murine Sepsis Model Induced by Cecal Ligation and Puncture
-
Han SH, Kim JS, Woo JH, Jeong SJ, Shin JS, Ahn YS, Kim JM
- KMID: 2352796
- Yonsei Med J.
- 2015 Jan;56(1):112-123.
- doi: 10.3349/ymj.2015.56.1.112
PURPOSE: Although the proteasome inhibitor known as bortezomib can modulate the inflammatory process through the nuclear factor-kappa B signaling pathway, the immunomodulatory effect of pre-incubated bortezomib has not been fully... -
- CITED
-
- Close
- SHARE
-
- Close
- The Effect of Bortezomib on Antibody-Mediated Rejection after Kidney Transplantation
-
Lee J, Kim BS, Park Y, Lee JG, Lim BJ, Jeong HJ, Kim YS, Huh KH
- KMID: 2345894
- Yonsei Med J.
- 2015 Nov;56(6):1638-1642.
- doi: 10.3349/ymj.2015.56.6.1638
PURPOSE: Recently, bortezomib has been used to treat antibody-mediated rejection (AMR) refractory to conventional treatment such as plasmapheresis, intravenous immunoglobulin, and rituximab. The authors aimed to describe their experiences when... -
- CITED
-
- Close
- SHARE
-
- Close
